Vivoryon Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Frank Weber
Chief executive officer
€1.1m
Total compensation
| CEO salary percentage | 22.30% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | 4.3yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully
Dec 05
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 28Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 04Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 02Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
Jan 26Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 16We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth
May 10Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?
Mar 11We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely
Jan 14
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €1m | €256k | -€21m |
| Sep 30 2024 | n/a | n/a | -€26m |
| Jun 30 2024 | n/a | n/a | -€31m |
| Mar 31 2024 | n/a | n/a | -€30m |
| Dec 31 2023 | €528k | €86k | -€28m |
Compensation vs Market: Frank's total compensation ($USD1.30M) is above average for companies of similar size in the Dutch market ($USD424.01K).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Weber (64 yo)
Dr. Frank T. Weber M. D. has been Chief Medical and Development Officer (CMDO) of Vivoryon Therapeutics N. V. (formerly known as Vivoryon Therapeutics AG & Probiodrug AG) since September 1, 2019. He serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Medical Officer & Executive Director | 1.8yrs | €1.15m | no data | |
| CFO & Executive Director | 1.2yrs | €922.00k | no data | |
| Chief Business Officer & Executive Director | 6.8yrs | €577.00k | no data | |
| Chief Operating Officer & Executive Board Member | no data | no data | no data | |
| Director of Investor Relations & Communications | no data | no data | no data | |
| Co-Founder & Advisor | no data | €222.11k | no data | |
| Advisor | no data | €319.20k | no data |
Experienced Management: VVY's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Medical Officer & Executive Director | 1.7yrs | €1.15m | no data | |
| CFO & Executive Director | 1.7yrs | €922.00k | no data | |
| Chief Business Officer & Executive Director | no data | €577.00k | no data | |
| Chief Operating Officer & Executive Board Member | less than a year | no data | no data | |
| Independent Non-Executive Chairman | no data | €105.00k | 0.87% € 399.7k | |
| Independent Vice Chairman of the Board | less than a year | €95.00k | no data | |
| Independent Non-Executive Director | 2.9yrs | €136.00k | no data | |
| Independent Non-Executive Director | 2.9yrs | €113.00k | 0.0038% € 1.8k |
Experienced Board: VVY's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 01:44 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivoryon Therapeutics N.V. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lucy-Emma Mary Codrington-Bartlett | Jefferies LLC |
| Christian Ehmann | Warburg Research GmbH |